Tissue Regenix Group says it is well positioned for the second half of 2022, having increased revenue and narrowed losses. The regenerative medical specialists, whose patented decellularisation technology removes DNA and other cellular material from soft tissue so that it is not rejected by a patient’s body, told shareholders it had built revenue by 25% to £10.2m ($11.8) and reduced adjusted...
Tissue Regenix narrows losses but lingering impact of Covid weighs on healthcare market
T